Aug. 6 at 6:33 PM
$BCTX It has been many years in the making, but this is certainly among the most pivotal milestones for BriaCell.
Bria-IMT, Bria-OTS and Bria-BRES are all different iterations of the same SV-BR-1-GM cell line for breast cancer. And, while they have advanced the technology to engineer the expression of specific HLA-types and and other cytokines & costimulatory molecules, one of the greatest remaining questions has always been whether the same approach and technology could be translated to other, non-proprietary cell lines.
This is the first step in the evolution from a novel breast cancer therapy into a new, multi-indication therapeutic platform.
Long ways to go, but a critical step forward.
